Second trimester maternal serum biochemical screening for Down's syndrome: experience of a single obstetric unit.

The objective of this study was to assess the effects of mid-trimester biochemical screening on the prenatal diagnosis of Down's syndrome. All patients booked for antenatal care at the Royal Free Hospital are offered a double marker biochemical screening test (alpha-fetoprotein and free beta human chorionic gonadotrophin). The results of double marker screening tests and the notes of all cases of trisomy 21 from 1 April 1993 to 31 March 1995 were reviewed. Of the 6170 women booked in the antenatal clinic during this 2-year period 4427 (71.8%) took up the offer of biochemical screening. Four hundred and twenty-nine (9.7% of those screened) were reported positive and 293 karyotypes were performed in this group (68.3% uptake) and 253 karyotypes were also performed for other indications. Thirteen of 21 affected pregnancies had biochemical screening. The detection rate of biochemical screening in women aged <37 years was 0% (0/2) with a 8.4% false positive rate. In women aged 37 years the detection rate was 100% (11/11) with a false positive rate of 23%. The overall detection rate for Down's syndrome was 84.6% and the false positive rate was 9.5%. In conclusion, biochemical screening successfully targeted affected pregnancies in women aged 37 years and was useful in reducing the fetal karyotyping rate. However, it was disappointing in the prenatal diagnosis of trisomy 21 in women <37 years old.

[1]  R. Weiss,et al.  The advantages of using triple-marker screening for chromosomal abnormalities. , 1995, American journal of obstetrics and gynecology.

[2]  J. Haddow,et al.  Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening , 1994, The New England journal of medicine.

[3]  K. Spencer,et al.  Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin. , 1993, BMJ.

[4]  T. Marteau.  Psychological consequences of screening for Down's syndrome. , 1993, BMJ.

[5]  D. Luthy,et al.  A Prospective Evaluation of a Second-Trimester Screening Test for Fetal Down Syndrome Using Maternal Serum Alpha-Fetoprotein, hCG, and Unconjugated Estriol , 1993, Obstetrics and gynecology.

[6]  P. Leymarie,et al.  Screening for fetal Down syndrome with maternal serum hCG and oestriol: A prospective study , 1992, Prenatal diagnosis.

[7]  J. Simpson,et al.  Maternal Serum Screening for Fetal Down Syndrome in Women Less Than 35 Years of Age Using Alpha-Fetoprotein, hCG, and Unconjugated Estriol: A Prospective 2-Year Study , 1992, Obstetrics and gynecology.

[8]  K. Spencer,et al.  Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers , 1992, Annals of clinical biochemistry.

[9]  J. Canick,et al.  Prenatal screening for Down's syndrome with use of maternal serum markers. , 1992, The New England journal of medicine.

[10]  N. Wald,et al.  Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. , 1992, BMJ.

[11]  Walter E. Johnson,et al.  An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities , 1984 .

[12]  L. Koulischer,et al.  A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood. , 1995, American journal of obstetrics and gynecology.

[13]  N. Migone,et al.  Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study , 1994, International journal of clinical & laboratory research.